Study funded by the Foundation's National Lupus Research Program secures NIH planning grant to develop a multi-center trial of mesenchymal stem cells.
Flare rates among participants receiving a low dose of the b-cell blocker did not meet primary endpoint but were lower for individuals receiving a higher dose.
An international group of lupus experts has developed a set of recommendations to implement the treat-to-target strategy for managing lupus.
Lupus Foundation of America announces its 2014 National Lupus Research Program Summer Fellowships and Career Development Awards
Bruce Richardson, M.D., Ph.D., of the University of Michigan, was honored for his research findings that have made significant contributions to the field and have a high likelihood of generating further insights in understanding the disease.
LFA-REAL will address major challenges in lupus treatment and disease management, and has the potential to greatly improve medical care and quality of life for people living with lupus.
Sandra C. Raymond, President and CEO of Lupus Foundation of America, was featured on BioCentury This Week to speak about lupus and the Accelerating Medicines Partnership (AMP). Watch now!
Lupus Foundation of America supported study finds combination therapy that includes hydroxychloroquine may be beneficial to pregnant patients with lupus and/or antiphospholipid syndrome.